The American-based company Cannabis Inc., which specializes in the production of cannabinoid-based medicines, declared that its expansion plans are in top gear and soon it would launch a third medical marijuana dispensary in California.
According to the company, preparation of the final documents is at advanced stage to finalize the integration of its third medical marijuana functions for the California market opening.
Starting January 2018, Cannabis Science sought to prelaunch sales of its own proprietary blockchain and would launch ICO trading with a unique three-symbol trading symbol on various blockchain currency exchange markets after the completion of pre-launch sales. The Cannabis Science blockchain whitepapers were released in January 2018.
“We are on track and on schedule to open the first two dispensaries in Los Angeles market beginning January 2018 and we expect this latest market acquisition to complete and be ready for opening shortly thereafter. It will be an interesting integration with our Cannabis Science Asset-backed Blockchain Cryptocurrency ICO,” said Raymond C. Dabney, President, CEO, and co-Founder of Cannabis Science Inc.
Asset-Backed Blockchain ICO
By January 2018, the company planned pre-launch sales of their own proprietary CBIS asset-backed blockchain. According to Mr. Dabney, the company has is discovering new frontiers with the blockchain technology.
“We have been in the industry for some time now; we certainly believe that we have found something special for this blockchain arena, not just for the cannabis industry, but for so many unexplored industries and applications. This endeavor is outstanding for Cannabis Science for a number of reasons as our blockchain currency can be backed with real world assets for additional ICO trading security and comfort. Bitcoin has risen 1500% this year, about 85% in the last few weeks and Futures contracts open as of yesterday.”
As more companies and organizations adopt the blockchain technology for their projects, the Cannabis Science Inc. is not left behind. The company has a unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory.